I am a
Home I AM A Search Login

Papers of the Week

2022 Apr 01

Cochrane Database Syst Rev


Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.


Nevitt SJ, Sudell M, Cividini S, Marson AG, Tudur Smith C
Cochrane Database Syst Rev. 2022 Apr 01; 4:CD011412.
PMID: 35363878.


This is an updated version of the original Cochrane Review published in 2017. Epilepsy is a common neurological condition with a worldwide prevalence of around 1%. Approximately 60% to 70% of people with epilepsy will achieve a longer-term remission from seizures, and most achieve that remission shortly after starting antiepileptic drug treatment. Most people with epilepsy are treated with a single antiepileptic drug (monotherapy) and current guidelines from the National Institute for Health and Care Excellence (NICE) in the United Kingdom for adults and children recommend carbamazepine or lamotrigine as first-line treatment for focal onset seizures and sodium valproate for generalised onset seizures; however, a range of other antiepileptic drug (AED) treatments are available, and evidence is needed regarding their comparative effectiveness in order to inform treatment choices.